Pal, Sebely
McKay, Jenny
Ho, Suleen
Jane, Monica
Gahler, Roland J.
Wood, Simon
Funding for this research was provided by:
Factors Group Australia Pty Ltd
Article History
Received: 17 February 2021
Accepted: 8 April 2022
First Online: 3 May 2022
Declarations
:
: Ethics approval was gained for this study as a part of the larger study from the Curtin University Human Research Ethics Committee (HREC) on 23 November 2011, approval number: HR41/2011. All components of the present study strictly adhered to the HREC guidelines. All participants provided signed, written informed consent, and were made aware that their participation was voluntary and that they could withdraw from the study at any time. Ongoing privacy, security and protection of the identity and information of participants was ensured for all future data collected as part of the present study. In addition, the larger clinical trial was registered with the Australian New Zealand Clinical Trial Registry on 20 April 2011, registration number: ACTRN12611000415909.
: Not applicable.
: SW receives consulting fees from InovoBiologic Inc, Canada. S Wood has an InovoBiologic Inc. patent pending. RJG is the owner of the Factors Group of Companies and holds various patents on PGX®. All other authors declare that they have no competing interests.